OQROGet OQRO Pro
Insider trade

Bridgebio Pharma (BBIO)Chief Accounting Officer sold ~$45K

Maricel Apuli, Chief Accounting Officer at Bridgebio Pharma, sold ~$45K of Bridgebio Pharma shares.

~$45K
Approx. value · 1,000 sh @ $45.44
142K
Holds after · shares reported
Traded
Aug 7, 2025
Filed
Aug 11, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 28, 2021Insider · 1 personInsiders: 2 purchases (~$30K)
  2. Dec 29, 2021InsiderDirector purchased ~$25K of BBIO shares in the open market
  3. Jun 10, 2025InsiderDirector sold ~$172K of BBIO shares in the open market
  4. Jun 24, 2025InsiderDirector sold ~$4.42M of BBIO shares in the open market
  5. Jun 26, 2025Insider · 1 personInsiders: 4 sales (~$207K)
  6. Jun 27, 2025Insider10% owner sold ~$154M of BBIO shares in the open market
  7. Jul 1, 2025Insider · 1 personInsiders: 4 sales (~$1.7M)
  8. Jul 2, 2025Insider · 1 personInsiders: 2 sales (~$1.7M)
  9. Aug 5, 2025InsiderDirector sold ~$841K of BBIO shares in the open market
  10. Aug 7, 2025 · this disclosureInsiderOfficer sold ~$45K of BBIO shares in the open market

What came next

  1. Aug 7, 2025Insider · 1 personInsiders: 4 sales (~$1.8M)
  2. Aug 8, 2025Insider · 2 peopleInsiders: 6 sales (~$13.4M)
  3. Aug 8, 2025CongressDisclosed purchase of BBIO — reported range $1,001 - $15,000
  4. Aug 11, 2025InsiderDirector sold ~$2.4M of BBIO shares in the open market
  5. Aug 18, 2025Insider · 1 personInsiders: 2 sales (~$872K)
  6. Aug 20, 2025Insider · 1 personInsiders: 2 sales (~$1.3M)
  7. Aug 21, 2025InsiderCFO sold ~$2.09M of BBIO shares in the open market
  8. Sep 4, 2025Insider · 1 personInsiders: 4 sales (~$2.1M)
  9. Sep 5, 2025Insider · 2 peopleInsiders: 7 sales (~$6.1M)
  10. Sep 22, 2025CongressDisclosed purchase of BBIO — reported range $1,001 - $15,000
  11. Oct 29, 2025Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Bridgebio Pharma

For Bridgebio Pharma, OQRO holds 17 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BBIO page.

Other recent filings by Maricel Apuli, Chief Accounting Officer

The full history of Maricel Apuli, Chief Accounting Officer is on the profile page.

How this filing works

Other disclosures at Bridgebio Pharma

Everything OQRO holds on this company is on its BBIO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data